Sexually transmitted infections and risk of prostate cancer: Review of historical and emerging hypotheses

Future Oncology

Volumn 6, Issue 8, 2010, Pages 1289-1311

  Sutcliffe, Siobhan ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Chlamydia trachomatis; gonorrhea; herpesvirus; human papillomavirus; prostate cancer; sexually transmitted infection; syphilis; Trichomonas vaginalis

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER RISK; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONDYLOMA ACUMINATUM; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DRUG CARCINOGENICITY; EPSTEIN BARR VIRUS INFECTION; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATITIS; REVIEW; SELF REPORT; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VIRUS PATHOGENESIS;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES;

EID: 77956299351     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.95     Document Type: Review

References (116)

1. Ravich A, Ravich RA: Prophylaxis of cancer of the prostate, penis, and cervix by circumcision. NY State J. Med. 51, 1519-1520 (1951).
2. Ravich A: Cancer of prostate; its relationship to circumcision. Acta Unio Int. Contra Cancrum 8, 351-353 (1952).
3. Lancaster HO: The mortality in Australia from cancers peculiar to the male. Med. J. Aust. 2, 41-44 (1952).
4. King H, Diamond E, Lilieneld AM: Some epidemiological aspects of cancer of the prostate. J. Chronic Dis. 16, 117-153 (1963).
5. Quisenberry WB: Sociocultural factors in cancer in Hawaii. Ann. NY Acad. Sci. 84, 795-806 (1960).
6. Steele R, Lees RE, Kraus AS, Rao C: Sexual factors in the epidemiology of cancer of the prostate. J. Chronic Dis. 24, 29-37 (1971).
7. Krain LS: Some epidemiologic variables in prostatic carcinoma in California. Prev. Med. 3, 154-159 (1974).
8. Mandel JS, Schuman LM: Sexual factors and prostatic cancer: results from a case- control study. J. Gerontol. 42, 259-264 (1987).
9. Heshmat MY, Kovi J, Herson J, Jones GW, Jackson MA: Epidemiologic association between gonorrhea and prostatic carcinoma. Urology 6, 457-460 (1975).
10. Wynder EL, Mabuchi K, Whitmore WF Jr: Epidemiology of cancer of the prostate. Cancer 28, 344-360 (1971).
11. Heshmat MY, Herson J, Kovi J, Niles R: An epidemiologic study of gonorrhea and cancer of the prostate gland. Med. Ann. Dist. Columbia 42, 378-383 (1973).
12. De Marzo AM, Platz EA, Sutcliffe S et al.: Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (2007).
13. Harkness AH: Discussion on non-specific prostatitis. Proc. R. Soc. Med. 48, 413-424 (1955).
14. Lees RE, Steele R, Wardle D: Arsenic, syphilis, and cancer of the prostate. J. Epidemiol. Community Health 39, 227-230 (1985).
15. Bushman W : Etiology of prostatitis. Prostatic Diseases. Lepor H (Ed.). WB Saunders Company, PA, USA 552-553 (2000).
16. Herbert JT, Birkhoff JD, Feorino PM, Caldwell GG: Herpes simplex virus type 2 and cancer of the prostate. J. Urol. 116, 611-612 (1976).
17. Baker LH, Mebust WK, Chin TD, Chapman AL, Hinthorn D, Towle D: The relationship of herpesvirus to carcinoma of the prostate. J. Urol. 125, 370-374 (1981).
18. Haid M, Sharon N: Immunofluorescent evidence of prior herpes simplex virus type-2 infection in prostate carcinoma. Urology 24, 623-625 (1984).
19. Sanford EJ, Geder L, Laychock A, Rohner TJ Jr, Rapp F: Evidence for the association of cytomegalovirus with carcinoma of the prostate. J. Urol. 118, 789-792 (1977).
20. Boldogh I, Baskar JF, Mar EC, Huang ES: Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. J. Natl Cancer Inst. 70, 819-826 (1983).
21. Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE: Case-control studies of prostate cancer in blacks and whites in southern California. J. Natl Cancer Inst. 78, 869-874 (1987)
22. Niijima T, Koiso K: Incidence of prostatic cancer in Japan and Asia. Scand. J. Urol. Nephrol. Suppl. 55, 17-21 (1980).
23. Mishina T, Watanabe H, Araki H, Nakao M: Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 6, 423-436 (1985).
24. Fincham SM, Hill GB, Hanson J, Wijayasinghe C: Epidemiology of prostatic cancer: a case-control study. Prostate 17, 189-206 (1990).
25. Oishi K, Okada K, Yoshida O et al.: A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors. Prostate 17, 269-279 (1990).
26. Jackson MA, Kovi J, Heshmat MY, Jones GW, Rao MS, Ahluwalia BS: Factors involved in the high incidence of prostatic cancer among American blacks. Prog. Clin. Biol. Res. 53, 111-132 (1981).
27. Feminella JG, Lattimer JK: An apparent increase in genital carcinomas among wives of men with prostatic carcinomas: an epidemiologic survey. Pirquet Bull. Clin. Med. 20, 3-10 (1975).
28. Greenwald P, Kirmss V, Burnett WS: Prostate cancer epidemiology: widowerhood and cancer in spouses. J. Natl Cancer Inst. 62, 1131-1136 (1979).
29. Centers for Disease Control and Prevention: Sexually Transmitted Disease Surveillance, 2008. US Department of Health and Human Services, GA, USA (2009).
30. Stamm LV: Biology of Treponema pallidum. Sexually Transmitted Diseases (3rd Edition). Holmes K, Sparling P, Mardh P et al. (Eds). The McGraw-Hill Companies, Inc, NY, USA, 467 (1999).
31. Pelouze PS: The causes of complications. Gonorrhea in the Male and Female: a Book for Practitioners (2nd Edition). WB Saunders Company, PA, USA, 124-129 (1935).
32. Sutcliffe S, Platz EA: Inflammation and prostate cancer: a focus on infections. Curr. Urol. Rep. 9, 243-249 (2008).
33. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int. J. Cancer 121, 1571-1578 (2007).
34. Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ: Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J. Clin. Microbiol. 22, 641-644 (1985).
35. Fleming DT, McQuillan GM, Johnson RE et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337, 1105-1111 (1997).
36. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D: Risk factors for prostate cancer: a case-control study n Greece. Int. J. Cancer 80, 699-703 (1999).
37. Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK: Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case-control study in Wayne County, Michigan. Cancer Causes Control 16, 263-273 (2005).
38. Lightfoot N, Conlon M, Kreiger N, Sass-Kortsak A, Purdham J, Darlington G: Medical history, sexual, and maturational factors and prostate cancer risk. Ann. Epidemiol. 14, 655-662 (2004).
39. Fernandez L, Galan Y, Jimenez R et al.: Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: a case-control study in Cuba. Int. J. Epidemiol. 34, 193-197 (2005).
40. Ilic M, Vlajinac H, Marinkovic J: Case-control study of risk factors for prostate cancer. Br. J. Cancer 74, 1682-1686 (1996).
41. Hayes RB, Pottern LM, Strickler H et al.: Sexual behaviour, STDs and risks for prostate cancer. Br. J. Cancer 82, 718-725 (2000).
42. Rosenblatt KA, Wicklund KG, Stanford JL: Sexual factors and the risk of prostate cancer. Am. J. Epidemiol. 153, 1152-1158 (2001).
43. Sarma AV, McLaughlin JC, Wallner LP et al.: Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J. Urol. 176, 1108-1113 (2006).
44. Honda GD, Bernstein L, Ross RK, Greenland S, Gerkins V, Henderson BE: Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. Br. J. Cancer 57, 326-331 (1988).
45. Checkoway H, DiFerdinando G, Hulka BS, Mickey DD: Medical, life-style, and occupational risk factors for prostate cancer. Prostate 10, 79-88 (1987).
46. Hayes RB, de Jong FH, Raatgever J et al.: Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur. J. Cancer Prev. 1, 239-245 (1992).
47. Ewings P, Bowie C: A case-control study of cancer of the prostate in Somerset and east Devon. Br. J. Cancer 74, 661-666 (1996).
48. Pelucchi C, Talamini R, Negri E, Franceschi S, La Vecchia C: Genital and urinary tract diseases and prostate cancer risk. Eur. J. Cancer Prev. 15, 254-257 (2006).
49. La Vecchia C, Franceschi S, Talamini R, Negri E, Boyle P, D Avanzo B: Marital status, indicators of sexual activity and prostatic cancer. J. Epidemiol. Community Health 47, 450-453 (1993).
50. Newell GR, Fueger JJ, Spitz MR, Babaian RJ: A case-control study of prostate cancer. Am. J. Epidemiol. 130, 395-398 (1989).
51. Hiatt RA, Armstrong MA, Klatsky AL, Sidney S: Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 5, 66-72 (1994).
52. Michalek AM, Mahoney MC, McLaughlin CC, Murphy D, Metzger BB: Historical and contemporary correlates of syphilis and cancer. Int. J. Epidemiol. 23, 381-385 (1994).
53. Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13, 72-79 (2002)
54. Wolf R, Freedman D: Cigarette smoking, sexually transmitted diseases, and HIV/AIDS. Int. J. Dermatol. 39, 1-9 (2000).
55. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA: Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 2160-2166 (2006).
56. Huang WY, Hayes R, Pfeiffer R et al.: Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 17, 2374-2381 (2008).
57. Cheng I, Witte JS, Jacobsen SJ et al.: Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men s Health Study. PLoS One 5, E8736 (2010).
58. Sutcliffe S, Giovannucci E, Gaydos CA et al.: Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol. Biomarkers Prev. 16, 1573-1580 (2007).
59. Human Papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol.64. IARC, Lyon, France (1995).
60. McNicol PJ, Dodd JG: Detection of papillomavirus DNA in human prostatic tissue by Southern blot analysis. Can. J. Microbiol. 36, 359-362 (1990).
61. McNicol PJ, Dodd JG: Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. J. Clin. Microbiol. 28, 409-412 (1990).
62. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res. 52, 5991-5996 (1992).
63. Dillner J, Knekt P, Boman J et al.: Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int. J. Cancer 75, 564-567 (1998).
64. Hisada M, Rabkin CS, Strickler HD, Wright WE, Christianson RE, van den Berg BJ: Human papillomavirus antibody and risk of prostate cancer. JAMA. 283, 340-341 (2000).
65. Strickler HD, Goedert JJ: Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol. Rev. 23, 144-151 (2001).
66. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL: Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 763-768 (2003).
67. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J: Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 12, 872-875 (2003).
68. Carozzi F, Lombardi FC, Zendron P et al.: Association of human papillomavirus with prostate cancer: analysis of a consecutive series of prostate biopsies. Int. J. Biol. Markers. 19, 257-261 (2004).
69. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K: Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5, 15 (2005).
70. Korodi Z, Dillner J, Jellum E et al.: Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol. Biomarkers Prev. 14, 2952-2955 (2005).
71. Sitas F, Urban M, Stein L et al.: The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect. Agent Cancer 2, 6 (2007).
72. Bergh J, Marklund I, Gustavsson C et al.: No link between viral findings in the prostate and subsequent cancer development. Br. J. Cancer 96, 137-139 (2007).
73. Dennis LK, Coughlin JA, McKinnon BC et al.: Sexually transmitted infections and prostate cancer among men in the USA military. Cancer Epidemiol. Biomarkers Prev. 18, 2665-2671 (2009).
74. Sutcliffe S, Viscidi RP, Till C et al.: Human papillomavirus types 16, 18 and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol. Biomarkers Prev. 19, 614-618 (2010).
75. Leskinen MJ, Vainionp R, Syrjnen S et al.: Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 61, 397-401 (2003).
76. Balis V, Sourvinos G, Soulitzis N, Giannikaki E, Sofras F, Spandidos DA: Prevalence of BK virus and human papillomavirus in human prostate cancer. Int. J. Biol. Markers. 22, 245-251 (2007).
77. Sfanos KS, Sauvageot J, Fedor HL, Dick JD,De Marzo AM, Isaacs WB: A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patientswith prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 68, 306-320 (2008).
78. Gazzaz FS, Mosli HA: Lack of detection of human papillomavirus infection by hybridization test in prostatic biopsies. Saudi Med. J. 30, 633-637 (2009)
79. Silvestre RV, Leal MF, Demachki S et al.: Low frequency of human papillomavirus detection in prostate tissue from individuals from Northern Brazil. Mem Inst Oswaldo Cruz. 104, 665-667 (2009).
80. Boyle P, Levin B: Chronic infections. World Cancer Report. International Agency for Research on Cancer, Lyon, France 131 (2008).
81. Monini P, de Lellis L, Fabris M, Rigolin F, Cassai E: Kaposi s sarcoma-associated herpesvirus DNA sequences in prostate tissueand human semen. N. Engl. J. Med. 334, 1168-1172 (1996).
82. Sitas F, Carrara H, Beral V et al.: Antibodies against human herpesvirus 8 in black South African patients with cancer. N. Engl. J. Med. 340, 1863-1871 (1999).
83. Tasaka T, Said JW, Morosetti R et al.: Is Kaposi s sarcoma-associated herpesvirus ubiquitous in urogenital and prostate tissues? Blood 89, 1686-1689 (1997).
84. Lebbe C, Pellet C, Tatoud R et al.: Absence of human herpesvirus 8 sequences in prostate specimens. AIDS 11, 270 (1997)
85. Hoffman LJ, Bunker CH, Pellett PE et al.: Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J. Infect Dis. 189, 15-20 (2004).
86. Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J: No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J. Infect Dis. 191, 2008-2011 (2005).
87. Jenkins FJ, Hayes RB, Jackson A et al.: Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects. J. Infect Dis. 196, 208-211 (2007).
88. Berrington de Gonzalez A, Urban MI et al.: Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: a case-control study. Infect. Agent Cancer 1, 2 (2006).
89. Anttila T, Tenkanen L, Lumme S et al.: Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 14, 385-389 (2005).
90. Krieger JN: Trichomoniasis in men: old issues and new data. Sex. Transm. Dis. 22, 83-96 (1995).
91. Krieger JN, Alderete JF: Trichomonasvaginalis and trichomoniasis. In: Sexually Transmitted Diseases. Holmes K, Sparling P, Mardh P et al. (Eds). The McGraw-HillCompanies, Inc., NY, USA 587-604 (1999).
92. Perl G, Schapira HE, Ragazzoni H: Male urogenital trichomoniasis. J. Mt Sinai Hosp. NY 32, 495-506 (1965).
93. Gardner WA Jr, Culberson DE: Pathology of urogenital trichomoniasis in men. In: Trichomonads Parasitic in Humans. Honigberg BM (Ed.) Springer-Verlag, NY, USA, 291-296 (1990).
94. Smith CJ, Gardner WA Jr: Inflammationproliferation: possible relationships in the prostate. In: Current Concepts and Approaches to the Study of Prostate Cancer. Coffey DS, Gardner WA Jr, Resnick MI, Karr JP (Eds). Alan R Liss, Inc., NY, USA, 317-325 (1987).
95. Sutcliffe S, Giovannucci E, Alderete JF et al.: Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 939-945 (2006).
96. Burke ET: Acute urethral gonorrhoea and its local complications in the male. Venereal Diseases. HK Lewis & Co. Ltd, London, UK 363 (1940).
97. Allen E, Jensen LB, Wood IH: Clinical and bacteriologic observations in Trichomonas vaginitis. Am. J. Obstet Gynecol. 30, 565-570 (1935).
98. Drummond A: Trichomonas infestation of the prostate gland. Am. J. Surg. 31, 98-103 (1936).
99. Coutts WE, Silva-Inzunza E, Tallman B: Genito-urinary complications of nongonococcal urethritis and trichomoniasis in males. Urol. Int. 9, 189-208 (1959).
100. Kostic PK: The importance of study of trichomonas infection in the male. Urol. Int. 9, 171-177 (1959).
101. Watt L, Jennison RF: Incidence of Trichomonas vaginalis in marital partners. Br. J. Vener. Dis. 36, 163-166 (1960).
102. Weston TET, Nicol CS: Natural history of trichomonal infection in males. Br. J. Vener. Dis. 39, 251-257 (1963).
103. Guenthner PC, Secor WE, Dezzutti CS: Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect. Immun. 73, 4155-4160 (2005).
104. Alderete JF, Garza GE: Specific nature of Trichomonas vaginalis parasitism of host cell surfaces. Infect. Immun. 50, 701-708 (1985).
105. Gilbert RO, Elia G, Beach DH, Klaessig S, Singh BN: Cytopathogenic effect of Trichomonas vaginalis on human vaginal epithelial cells cultured in vitro. Infect. Immun. 68, 4200-4206 (2000).
106. Rendon-Maldonado JG, Espinosa-Cantellano M, Gonzalez-Robles A, Martinez-Palomo A: Trichomonas vaginalis: in vitro phagocytosis of lactobacilli, vaginal epithelial cells, leukocytes, and erythrocytes. Exp Parasitol. 89, 241-250 (1998).
107. Kucknoor A, Mundodi V, Alderete JF: Trichomonas vaginalis adherence mediates differential gene expression in human vaginal epithelial cells. Cell Microbiol. 7, 887-897 (2005).
108. Sutcliffe S, Alderete JF, Till C et al.: Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int. J. Cancer 124, 2082-2087 (2009).
109. Stark JR, Judson G, Alderete JF et al.: Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians Health Study. J. Natl Cancer Inst. 101, 1406-1411 (2009).
110. Blacklock NJ: Anatomical factors in prostatitis. Br. J. Urol. 46, 47-54 (1974).
111. Hong S, Klein EA, Das Gupta J et al.: Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J. Virol. 83, 6995-7003 (2009).
112. Urisman A, Molinaro RJ, Fischer N et al.: Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, E25 (2006).
113. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR: XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl Acad. Sci. USA 106, 16351-16356 (2009).
114. Fischer N, Hellwinkel O, Schulz C et al.: Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J. Clin. Virol. 43, 277-283 (2008).
115. Strickler HD, Burk R, Shah K et al.: A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 82, 1118-1125 (1998).
116. Strickler HD, Schiffman MH, Shah KV et al.: A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer Prev. 7, 305-313 (1998).